Show menu

A Global Trading Solution for Investors and Opportunity for Nordic Life Science Companies

Thanks! Share it with your friends!

You disliked this video. Thanks for the feedback!

Added by vindheim
147 Views
Accessing US capital is, more often than not, a key strategic consideration for European life sciences companies. For publicly listed companies on European exchanges, this can be even more of a challenge - how can you make it easier for US investors to buy your stock?

Cross-trading on an OTC market can solve this problem, providing access to US capital and liquidity, and provide a springboard for a future US listing. A great opportunity for companies to consider and understand as a route to capital, liquidity and US exposure, our expert panel discuss...

• When should a company consider cross-trading? Benefits of access and exposure to American investors
• The synergy between Nasdaq Nordics and OTC Market
• How cross trading can increase volume and liquidity on your local exchange due to US investor access?


Nikolaj Sørensen, CEO, Orexo
Joe Coveney, VP Corporate Services, OTC Markets Group
Adam Kostyal, SVP, Nasdaq
Marius Halvorsen, Head of Investment Banking, Arctic Securities
Moderator: Josh Dance, SVP, LSX

The LSX channel features sessions from LSX events, where our mission is to connect senior #biotech, #medtech & #healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.

Subscribe to our channel for more videos.

Follow us on Twitter: https://twitter.com/LSXLeaders

Visit us at www.lsxleaders.com
Category
ATLANTIC ROAD
Commenting disabled.